Investor Information
Event: April 02, 2013 EDAP TMS is presently accelerating adoption of HIFU therapy as a new standard of care for localized prostate cancer in Europe where the company is the clear market leader while securing US approval through an active FDA Clinical Study at leading urology centers.
Recent Releases
May 16, 2013
EDAP Reports 23% Increase in First Quarter 2013 Revenues
May 14, 2013
EDAP's Ablatherm-HIFU Receives Two Best Poster Awards at 2013 American Urological Association Annual Meeting
Media Coverage
Robotic Ablatherm HIFU's Importance in
Prostate Cancer Surgeries Featured in Major
Conferences
Events & Presentations
May 16, 2013 at 8:30 AM ET
EDAP First Quarter 2013 Results Conference Call
Nov 21, 2012 at 8:30 AM ET
EDAP Third Quarter 2012 Results Conference Call
IR Contact
Stock Information
|
NASDAQ : EDAP Last Price : 4.18 Change : 0.41  10.875%Day High : 4.18 Day Low : 3.81 Year High : 4.94 Year Low : 1.43 Volume : 259,800 |